Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Radiotherapy in Advanced NSCLC
NCT04549428Phase 2Terminated
- Sponsor
- Istituto Oncologico della Svizzera Italiana
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Istituto Oncologico della Svizzera Italiana. Primary endpoint: Objective Response Rate at 3 months. Started Oct 2020; status: terminated.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04549428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549428.